News

A cross-sectional study explores how full-benefit dual-eligible beneficiaries differ across MA plans with differing levels of Medicaid coordination and integration.

In the second part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, details what the company’s data reveals about the relationship between pharmacy access and broader health disparities in underserved communities.

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’

In the first part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, explains how geospatial mapping can help identify and address emerging pharmacy deserts across the United States.

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.

In the final part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, discusses how uncertainty can help reshape the way organizations prioritize supply chain investments.

Direct-to-consumer and direct-to-patient models are major contributors.

In the fourth part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, explains how migrating to cloud-based systems can help overcome this challenge.

In the third part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, comments on the role of automation and GenAI evolving in workforce development.

The installation of the new vial, syringe, and cartridge line is expected to take place throughout the coming year.

In the second part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, discusses the common misconceptions supply chain leaders might have around the term, and why the processes around optimization need to change.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

In the first part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, describes the disparity in organizations utilizing supply-chain specific applications.

The designation allows pharmacists to substitute it for Humira without prescriber approval (per state law), which expands patient access in the process.

This serialization system represents a business imperative that yields significant competitive advantages.

The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

As this medical approach continues to become more widely adopted, the industry must adapt to help provide precise, compliant, temperature-controlled delivery of highly individualized treatments.

In the final part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes best practices for balancing long-term pipeline sustainability with short-term financial returns.

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by real-time data.

Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory strategy.

In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, explains how GLP-1 therapies’ success can influence future investment strategies in high unmet need areas.